Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

terminated150%
enrolling_by_invitation150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitation

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

NCT07474051
terminatedphase_1

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

NCT04633148

Clinical Trials (2)

Showing 2 of 2 trials
NCT07474051

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

Enrolling By Invitation
NCT04633148Phase 1

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

Terminated

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2